Posted by Michael Wonder on 06 Jul 2017
Vertex raises price of top-selling cystic fibrosis drug for first time
5 July 2017 - Vertex Pharmaceuticals has raised the price of its best-selling cystic fibrosis drug for the first time, in a move that could boost revenues at the Boston-based company.
The decision by Vertex to increase the list price of Orkambi by 5%, to around $273,000 per year before discounts, was first reported by Cowen analyst Phil Nadeau in a note on Wednesday morning and later confirmed by a spokeswoman for the company.
